Diagonal Bio (DIABIO) Q1 2025 earnings summary

Executive summary

• Achieved net sales of 186 KSEK in Q1 2025, up from 0 KSEK year-over-year, with capitalised development of 297 KSEK (250 KSEK).

• Operating loss improved to -2,529 KSEK from -2,727 KSEK year-over-year; EPS at -0.003 SEK (-0.07 SEK).

• Cash flow positive at 3,686 KSEK versus -1,116 KSEK in Q1 2024; cash position at period end was 4,504 KSEK (1,856 KSEK).

• Strengthened financial position via oversubscribed rights issue and directed share issues, raising SEK 7.7 million before costs.

• Transitioned listing from Nasdaq First North Growth Market to NGM Nordic SME to reduce costs and focus on sales and marketing.

Financial highlights

• Net sales: 186 KSEK (0 KSEK year-over-year); capitalised development: 297 KSEK (250 KSEK).

• Operating loss: -2,529 KSEK (-2,727 KSEK year-over-year); net loss after financial items: -2,529 KSEK (-2,989 KSEK).

• Cash flow for the period: 3,686 KSEK (-1,116 KSEK year-over-year); cash and cash equivalents: 4,504 KSEK (1,856 KSEK).

• Investments in intangible assets: 65 KSEK (291 KSEK); development expenses: 297 KSEK (250 KSEK).

• Share capital at period end: 3,998 KSEK; total equity: 28,390 KSEK.

Outlook and guidance

• Positioned for accelerated growth with validated products, strong partnerships, and expanded market presence in equine diagnostics.

• Focus on commercialising LAMPlify in laboratory and veterinary markets, with Panviral targeting in-vitro diagnostics pending regulatory approval.